📊 NNVC Key Takeaways
Is Nanoviricides, Inc.. (NNVC) a Good Investment?
NNVC is a pre-revenue pharmaceutical company with unsustainable cash burn of $5.6M annually against only $3.2M in cash, implying less than 7 months of runway. Negative operating income of $6.1M and negative returns on equity (-65.5%) and assets (-58.7%) indicate the company is destroying shareholder value with no offsetting revenue generation. Without near-term revenue inflection or additional capital, the company faces imminent financial distress.
NanoViricides is pre-revenue with persistent operating losses and negative ROE/ROA, indicating no current path to profitability. Liquidity is solid and liabilities are modest, but the cash burn and negative interest coverage point to a limited runway and likely need for additional financing. Without clear progress toward revenue generation or non-dilutive funding, fundamentals remain unfavorable.
Why Buy Nanoviricides, Inc.. Stock? NNVC Key Strengths
- Current ratio of 3.17x indicates adequate short-term liquidity position
- Debt-to-equity ratio of 0.52x is moderate and not overleveraged
- Low capital expenditures ($84.3K) suggest capital-efficient R&D model
- Strong liquidity with high current and quick ratios (4.43x)
- Low liabilities relative to assets and equity base
- Asset-light profile with minimal capex requirements
NNVC Stock Risks: Nanoviricides, Inc.. Investment Risks
- Zero revenue with negative operating cash flow of $5.6M creates unsustainable burn rate and ~7 month cash runway
- Cannot service debt obligations with operating losses; interest coverage is -121.7x
- Pre-revenue pharmaceutical business model carries execution risk with no visible commercialization path or revenue timeline
- No revenue and ongoing operating losses (pre-revenue risk)
- Cash burn drives limited runway and potential dilution
- Debt present with negative interest coverage indicating servicing risk
Key Metrics to Watch
- Cash balance trend and months of runway remaining
- Operating cash flow and quarterly burn rate acceleration/deceleration
- Regulatory milestones and clinical trial progress announcements
- Operating cash burn (OCF/FCF trend)
- Cash and equivalents (runway in months)
Nanoviricides, Inc.. (NNVC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.17x current ratio provides a solid financial cushion.
NNVC Profit Margin, ROE & Profitability Analysis
NNVC vs Healthcare Sector: How Nanoviricides, Inc.. Compares
How Nanoviricides, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Nanoviricides, Inc.. Stock Overvalued? NNVC Valuation Analysis 2026
Based on fundamental analysis, Nanoviricides, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Nanoviricides, Inc.. Balance Sheet: NNVC Debt, Cash & Liquidity
NNVC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Nanoviricides, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.70 indicates the company is currently unprofitable.
NNVC Revenue Growth, EPS Growth & YoY Performance
NNVC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | N/A | -$1.8M | $-0.09 |
| Q2 2026 | N/A | -$1.8M | $-0.11 |
| Q1 2026 | N/A | -$1.8M | $-0.10 |
| Q3 2025 | N/A | -$1.9M | $-0.14 |
| Q2 2025 | N/A | -$2.0M | $-0.14 |
| Q1 2025 | N/A | -$2.0M | $-0.17 |
| Q3 2024 | N/A | -$1.6M | $-0.15 |
| Q2 2024 | N/A | -$1.6M | $-0.15 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Nanoviricides, Inc.. Dividends, Buybacks & Capital Allocation
NNVC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Nanoviricides, Inc.. (CIK: 0001379006)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NNVC
What is the AI rating for NNVC?
Nanoviricides, Inc.. (NNVC) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NNVC's key strengths?
Claude: Current ratio of 3.17x indicates adequate short-term liquidity position. Debt-to-equity ratio of 0.52x is moderate and not overleveraged. ChatGPT: Strong liquidity with high current and quick ratios (4.43x). Low liabilities relative to assets and equity base.
What are the risks of investing in NNVC?
Claude: Zero revenue with negative operating cash flow of $5.6M creates unsustainable burn rate and ~7 month cash runway. Cannot service debt obligations with operating losses; interest coverage is -121.7x. ChatGPT: No revenue and ongoing operating losses (pre-revenue risk). Cash burn drives limited runway and potential dilution.
What is NNVC's revenue and growth?
Nanoviricides, Inc.. reported revenue of $0.0.
Does NNVC pay dividends?
Nanoviricides, Inc.. does not currently pay dividends.
Where can I find NNVC SEC filings?
Official SEC filings for Nanoviricides, Inc.. (CIK: 0001379006) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NNVC's EPS?
Nanoviricides, Inc.. has a diluted EPS of $-0.31.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NNVC a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Nanoviricides, Inc.. has a SELL rating with 84% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NNVC stock overvalued or undervalued?
Valuation metrics for NNVC: ROE of -65.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NNVC stock in 2026?
Our dual AI analysis gives Nanoviricides, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NNVC's free cash flow?
Nanoviricides, Inc..'s operating cash flow is $-5.6M, with capital expenditures of $84.3K.
How does NNVC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -65.5% (avg: 15%), current ratio 3.17 (avg: 2).